

Cover Story
FreeNews Analysis
The National Cancer Institute Harold Varmus will leave on March 31 is leaner, cleaner, and more focused than it was on July 12, 2010, the day he became its 14th director.
By Matthew Bin Han Ong
In Brief
Drugs & Targets


Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval











